Fredrik J. Swartling
Affiliations: | University of California, San Francisco, San Francisco, CA |
Google:
"Fredrik Swartling"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lu X, Zhong L, Lindell E, et al. (2023) Identification of ATF3 as a novel protective signature of quiescent colorectal tumor cells. Cell Death & Disease. 14: 676 |
| Mainwaring OJ, Weishaupt H, Zhao M, et al. (2023) ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors. Nature Communications. 14: 1221 |
| Borgenvik A, Holmberg KO, Bolin S, et al. (2022) Dormant SOX9-positive cells facilitate MYC-driven recurrence of medulloblastoma. Cancer Research |
| Weishaupt H, Čančer M, Rosén G, et al. (2022) Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas. Neuro-Oncology |
| Trieu KG, Tsai SY, Eberl M, et al. (2022) Basal cell carcinomas acquire secondary mutations to overcome dormancy and progress from microscopic to macroscopic disease. Cell Reports. 39: 110779 |
| Adolphe C, Millar A, Kojic M, et al. (2021) SOX9 defines distinct populations of cells in SHH medulloblastoma but is not required for Math1-driven tumour formation. Molecular Cancer Research : McR |
| Simonds EF, Lu ED, Badillo O, et al. (2021) Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. Journal For Immunotherapy of Cancer. 9 |
| Berg TJ, Marques C, Pantazopoulou V, et al. (2021) The irradiated brain microenvironment supports glioma stemness and survival via astrocyte-derived Transglutaminase 2. Cancer Research |
| Mainwaring O, Weishaupt H, Hutter S, et al. (2021) EMBR-07. MYC BUT NOT MYCN GENERATES AGGRESSIVE GROUP 3 MEDULLOBLASTOMA BY ARF PATHWAY SUPPRESSION Neuro-Oncology. 23: i7-i7 |
| Borgenvik A, Čančer M, Hutter S, et al. (2020) Targeting MYCN in Molecularly Defined Malignant Brain Tumors. Frontiers in Oncology. 10: 626751 |